T

hree years after the University of California and the Broad Institute began battling over key patents on CRISPR-Cas9 genome editing inventions, the fat lady is finally about to sing in this multimillion-dollar operatic battle.

The U.S. Court of Appeals for the Federal Circuit, which heard oral arguments in the case on Monday, is expected to rule within 90 days on whether the Broad can keep its foundational CRISPR patents, as the patent office ruled last year. (IP experts think the chances of the Supreme Court accepting the case, if the losing party tries that route, are comparable to those of the Baltimore Orioles winning the 2018 World Series.)

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy